Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin”